GSK’s Withdrawn Blood Cancer Drug Reduced Risk of Death in Trial
GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...
BioSpace2d
GSK Quits Trade Group BIO as Industry Faces Uncertain Political Future
GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...
FiercePharma5d
GSK calls it quits on trade group BIO for 2025, following exits by Takeda, UCB and more
GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...
standard-journal6d
ViiV Healthcare expands on real-world data supporting use of long-acting therapies in diverse patient populations at HIV Glasgow
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, will share new data from its industry-leading HIV treatment and prevention portfolio ...